EVE Health Group Limited (EVE.XA)
Cboe AU · AUD
A$0.013 (+18.18%) as of
Key statistics
- EPS (TTM)
- -0.0010
- 52-week range
- 0.0090 – 0.0320
- Beta
- 0.40
- Revenue (TTM)
- 1.15M
- Profit margin
- -163.97%
- Volume
- 258.65k
About EVE Health Group Limited
EVE Health Group Limited, a life sciences and healthcare company, engages in the development and commercialization of pharmaceutical products in Australia. It operates in two segments, Meluka (Branded Wellness Consumer Products) and Nextract (Pharmaceutical Products and Intellectual Property). Its lead product is the Dyspro, a formulation developed to address dysmenorrhoea and Endometriosis Pain; and Libbo, an oral dissolving film for erectile dysfunction. The company also develops Apixaban to treat anticoagulation. The company was formerly known as EVE Investments Limited. EVE Health Group Limited was incorporated in 2003 and is based in Subiaco, Australia.
- Headquarters
- Subiaco, WA, Australia
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.